Researcher.Life Logo

Annals of the Rheumatic Diseases : Impact Factor & More

eISSN: 1468-2060pISSN: 0003-4967

Aims and Scope of Annals of the Rheumatic Diseases

The Annals of the Rheumatic Diseases is a peer-reviewed medical journal. It is co-owned by the BMJ Group and the European League Against Rheumatism and covers all aspects of rheumatology, including musculoskeletal conditions, arthritis, and connective tissue diseases. The journal publishes basic, clinical, and translational research and abstracts from conferences. The journal was established in 1939. It is available online by subscription and archived editions of the journal (older than one year) are available free of charge. Each issue, the editor-in-chief selects a paper to be published open access as an "Editors Choice". The editor-in-chief is Josef Smolen. Less

Key Metrics

CiteScore
28.5
Eigenfactor
0.05 - 0.1
H-Index
272
Impact Factor
>= 25
Scite Index
0.88 5-Year SI
SJR
Q1Immunology
SNIP
5.22
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Annals of the Rheumatic Diseases

Annals of the Rheumatic Diseases Journal Specifications

Overview
Publisher BMJ PUBLISHING GROUP
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1935
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Annals of the Rheumatic Diseases ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Annals of the Rheumatic Diseases

A pathogenic gut lipoglycan drives systemic thromboinflammation in lupus nephritis.
  • 23 Apr 2027
  • Annals of the rheumatic diseases
EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis: 2025 update.
  • 25 Apr 2026
  • Annals of the rheumatic diseases
Corrigendum to Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: A target trial emulation study Ann Rheum Dis 2025;84(11):1938-1947.
  • 24 Apr 2026
  • Annals of the rheumatic diseases
Response of ultrasound-assessed synovitis to baricitinib, in monotherapy and combined with methotrexate, compared with etanercept in rheumatoid arthritis: a randomised, international, multicentre trial.
  • 22 Apr 2026
  • Annals of the rheumatic diseases
The evolving landscape of complement therapeutics in rheumatology.
  • 18 Apr 2026
  • Annals of the rheumatic diseases
Musculoskeletal ultrasound findings in people with asymptomatic hyperuricemia: baseline analysis from the Transitions in Gout Research (TIGER) study using the OMERACT gout ultrasound semiquantitative scoring system.
  • 18 Apr 2026
  • Annals of the rheumatic diseases
A pathogenic gut lipoglycan drives systemic thromboinflammation in lupus nephritis.
  • 23 Apr 2027
  • Annals of the rheumatic diseases
EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis: 2025 update.
  • 25 Apr 2026
  • Annals of the rheumatic diseases
Corrigendum to Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: A target trial emulation study Ann Rheum Dis 2025;84(11):1938-1947.
  • 24 Apr 2026
  • Annals of the rheumatic diseases
Response of ultrasound-assessed synovitis to baricitinib, in monotherapy and combined with methotrexate, compared with etanercept in rheumatoid arthritis: a randomised, international, multicentre trial.
  • 22 Apr 2026
  • Annals of the rheumatic diseases
The evolving landscape of complement therapeutics in rheumatology.
  • 18 Apr 2026
  • Annals of the rheumatic diseases
Musculoskeletal ultrasound findings in people with asymptomatic hyperuricemia: baseline analysis from the Transitions in Gout Research (TIGER) study using the OMERACT gout ultrasound semiquantitative scoring system.
  • 18 Apr 2026
  • Annals of the rheumatic diseases

FAQs on Annals of the Rheumatic Diseases